1.70
전일 마감가:
$1.75
열려 있는:
$1.71
하루 거래량:
28,496
Relative Volume:
0.25
시가총액:
$66.15M
수익:
$134.00K
순이익/손실:
$-9.93M
주가수익비율:
-5.00
EPS:
-0.34
순현금흐름:
$-6.72M
1주 성능:
-12.82%
1개월 성능:
-8.11%
6개월 성능:
-10.53%
1년 성능:
+1.80%
Entera Bio Ltd Stock (ENTX) Company Profile
명칭
Entera Bio Ltd
전화
972-2-532-7151
주소
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
ENTX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ENTX
Entera Bio Ltd
|
1.70 | 66.15M | 134.00K | -9.93M | -6.72M | -0.34 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2021-03-22 | 개시 | Aegis Capital | Buy |
Entera Bio Ltd 주식(ENTX)의 최신 뉴스
Entera Bio Reports Transformative Year in 2024 - TipRanks
Entera Bio Ltd. (ENTX) reports earnings - Quartz
Entera Bio Announces 2024 Financial Results and Updates - TipRanks
Entera Bio's Breakthrough: Oral Peptide Programs Show Promise as 2024 Results Reveal $21M War Chest - Stock Titan
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire
Entera Bio Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Entera Bio’s (ENTX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Opko Health, Entera Bio sign agreement for oral GLP-1/glucagon dual agonist peptide - BioWorld MedTech
OPKO and Entera team up on oral obesity candidate - The Pharma Letter
OPKO and Entera Bio partner on oral obesity treatment By Investing.com - Investing.com Australia
OPKO And Entera Bio Team Up For Game-Changing Obesity Pill - Finimize
OPKO and Entera partner to develop obesity pill -March 17, 2025 at 08:54 am EDT - Marketscreener.com
Entera Bio Collaborates with OPKO for Oral GLP-1/Glucagon - TipRanks
OPKO, Entera to Co-Develop Oral GLP-1/Glucagon Therapy for Obesity -March 17, 2025 at 08:38 am EDT - Marketscreener.com
OPKO and Entera Bio partner on oral obesity treatment - Investing.com India
OPKO Health and Entera Bio Enter into Collaboration - GlobeNewswire
Revolutionary Oral GLP-1 Obesity Treatment: OPKO and Entera Join Forces to Challenge Injectable Market - StockTitan
Revolutionary Oral GLP-1 Obesity Treatment: OPKO and Entera Bio Join Forces for Game-Changing Pill - Stock Titan
Entera Bio (ENTX) Expected to Announce Quarterly Earnings on Friday - Defense World
Entera Bio Ltd. to Host Earnings Call - ACCESS Newswire
Entera Bio to Participate in Upcoming Events - GlobeNewswire
Can Entera Bio's Upcoming Scientific Data Reshape Oral Peptide Therapy? Major Conference Schedule Revealed - Stock Titan
EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskel - The Manila Times
Could This Oral Osteoporosis Treatment Replace Daily Injections? Phase 2 Data Reveals Promising Results - StockTitan
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 31.6% in January - MarketBeat
US Penny Stocks: 3 Picks With Market Caps Over $60M - Yahoo Finance
Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Increase in Short Interest - MarketBeat
145,843 Shares in Entera Bio Ltd. (NASDAQ:ENTX) Acquired by Perigon Wealth Management LLC - MarketBeat
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 23.1% in January - MarketBeat
Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Entera Bio CEO to Present Business Updates at Oppenheimer Healthcare Conference - StockTitan
Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Decrease in Short Interest - Defense World
Entera Bio files Exhibit 5.1 with SEC By Investing.com - Investing.com South Africa
Entera Bio files Exhibit 5.1 with SEC - Investing.com
Entera Bio (NASDAQ:ENTX) Stock Price Up 1.1% – Still a Buy? - Defense World
Entera Bio (NASDAQ:ENTX) Shares Up 1.1%Time to Buy? - MarketBeat
Hypoparathyroidism Market Overview, Trends, Insights, - openPR
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate - Simply Wall St
Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Rises By 19.0% - MarketBeat
Knoll Capital Management, LLC's Strategic Acquisition in Entera Bio Ltd - GuruFocus.com
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update - MarketBeat
FY2024 EPS Estimate for Entera Bio Decreased by Analyst - MarketBeat
Entera Bio Ltd (ENTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):